NEW YORK (AP) -- Abraxis Bioscience Inc. said Wednesday it named Lex H.T. Van der Ploeg senior vice president of integrative medicine and translational science.
The move is connected with the company's plan to spin off Abraxis Health. Van der Ploeg will lead research and development efforts at Abraxis Health.
On Tuesday, the company said it would spin off Abraxis Health Inc. into an independent company with a focus on early-stage drug development. Meanwhile, the parent company will focus on the cancer drug Abraxane.
The company said Van der Ploeg most recently worked as the vice president of basic research and site head at Merck & Co., establishing a research laboratory in Boston while he was at the company.